Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Chronic vulval pain and vulvodynia

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
New severe pain still needs acute assessment

Rapid onset with fever, necrosis, urinary retention, ulceration, pregnancy-related pain, neurological deficit or an acute safeguarding concern is not explained by chronic vulvodynia.

Action: Assess observations, examine for infection, trauma and neurological disease with consent, obtain pregnancy or lesion tests where relevant, and use same-day acute gynaecology, urology or emergency referral before chronic-pain labelling.

Synopsis

Diagnose persistent vulval pain only after excluding specific disease, classify the pain phenotype, and build a realistic multidisciplinary plan addressing nerves, pelvic floor and psychosexual impact.

  • Vulvodynia is vulval pain lasting at least three months without a clear identifiable cause; it is a positive chronic-pain formulation reached after proportionate exclusion of specific disease.
  • Classify location as localised, generalised or mixed; stimulus as provoked, spontaneous or mixed; and record whether onset was primary or followed a pain-free period.
  • Burning, stinging, rawness, stabbing pain, allodynia and hyperalgesia can occur while the vulva looks normal; normal appearance does not mean the pain is imagined.
  • Use gentle cotton-bud mapping to record the distribution and intensity of evoked tenderness, but only after consent and never as a test of credibility.
  • Exclude candidiasis and other infection, lichen sclerosus or planus, dermatitis, genitourinary syndrome of menopause, neoplasia, trauma and neurological pain according to history and findings.
  • Assess pelvic-floor overactivity and inability to relax; physiotherapy should be specialist and may prioritise down-training, breathing and graded exposure rather than generic strengthening exercises.
  • Treatment is individualised and multimodal: explanation, vulval skin care, pelvic physiotherapy, psychosexual or cognitive behavioural therapy and selected local or systemic pain modifiers.
  • Medication evidence is limited: topical lidocaine can irritate and does not help everyone, while low-dose amitriptyline is off-label and requires slow titration and adverse-effect review.
  • Avoid repeated empirical antifungals after negative investigations and reserve vestibulectomy for exceptionally selected, localised refractory provoked disease in a specialist service.

Key red flags

A new ulcer, lump, pigmentation change, bleeding, induration, architectural change or non-healing lesion requires biopsy-oriented vulval assessment.

Fever, rapidly spreading erythema, necrosis, severe swelling, urinary retention or systemic illness suggests infection or another acute disorder.

New saddle sensory loss, leg weakness, bladder or bowel dysfunction or progressive neurological pain requires urgent neurological or spinal assessment.

Postmenopausal bleeding, unexplained weight loss, groin nodes or persistent focal night pain should not be attributed to vulvodynia without cancer exclusion.

Severe depression, suicidal thinking, trauma disclosure, coercion or intolerable functional decline requires prompt mental-health and safeguarding support.

Investigation priorities

01
Structured pain and impact assessmentFirst step

Classify location, provocation, onset, temporal pattern, severity and effect on function and relationships.

Management branches

DiagnosisExclude specific disease proportionately

Vulval pain has persisted or recurred for at least three months without an established explanation.

  1. Classify pain location, provocation, onset and timing and assess menstrual, menopausal, infection, skin, neurological, bladder, bowel and trauma context.
  2. Inspect the vulva and map tenderness with consent, using culture, STI testing, biopsy or imaging only when a clinical hypothesis supports each test.
  3. Name vulvodynia when no specific disorder explains the pain, while documenting and treating any coexisting condition separately.

Key medicines

Lidocaine topical ointmentApply 5% ointment thinly to the painful area daily or 15 to 20 minutes before a predictable trigger, then wash off before sexual contact.Local irritation is common and efficacy is inconsistent; avoid oral contact, prevent partner numbness and check product compatibility with barrier contraception.
AmitriptylineStart 10 mg orally at night and titrate in small increments according to benefit and tolerability, up to 100 mg daily under review.Evidence is limited; review sedation, anticholinergic effects, cardiac disease, interactions, pregnancy and overdose risk, and taper rather than stopping abruptly after prolonged use.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BASHH vulval conditions guideline 2024
  • NHS vulvodynia guidance
  • Cambridge University Hospitals vulvodynia physiotherapy guidance
  • Gloucestershire Hospitals vulvodynia guidance

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom